I agree with the content of the documents that reflects the constructive discussion of the meeting. Let me know if I can be of further help.

Best regards

[redacted]

Few comments: 1. in 2.1 at the end you mention ticlopidine which is in practice not available in the UK and was not truly studied in combination with rivaroxibam (if I understand well used in less than 1% of the patients recruited in ATLAS). I suggest deleting this point. 2. I think a further point should be added to the recommendations stating that **"Rivaroxibam has not been studied in combination with the newer antiplatelet agents Prasugrel and Ticagrelor. Recommendations for use of these agents have been addressed in previous NICE documents –quote NICE appraisal 236 etc-. At present the combined use of rivaroxibam with Prasugrel and Ticagrelor is not recommended." 3.** in 3.10 you state" vital status was unknown for 1117 (86.3%) patients". It is obviously the other way around (13.7%)